Suchergebnisse - "Daver, Naval"

PubPharm (634)

1

Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction : a single-centre, single-arm, phase 2 trial

enthalten in: The Lancet. Haematology | 2024

von Bazinet, A. | Kantarjian, H. | Bataller, A. | +17

2

Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms : Frequency and clinical implications

enthalten in: American journal of hematology | 2024

von Abuasab, T. | Borthakur, G. | Kanagal-Shamanna, R. | +15

3

Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia : a phase 2 study

enthalten in: The Lancet. Haematology | 2024

von Bazinet, A. | Garcia-Manero, G. | Short, N. | +22

4

Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression

enthalten in: British journal of haematology | 2024

von Jen, W. | Sasaki, K. | Loghavi, S. | +10

5

Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia

enthalten in: Cancer | 2024

von Jabbour, E. | Haddad, F. | Sasaki, K. | +16

6

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Rajakumaraswamy, N. | Gandhi, M. | Wei, A. | +8

7

Sotatercept for anemia of myelofibrosis : a phase II investigator-initiated study

enthalten in: Haematologica | 2024

von Bose, P. | Masarova, L. | Pemmaraju, N. | +21

8

Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Bazinet, A. | Desikan, S. | Li, Z. | +17

9

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

enthalten in: Leukemia | 2024

von Birdwell, C. | Fiskus, W. | Kadia, T. | +15

10

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib : final results

enthalten in: Blood advances | 2024

von Yacoub, A. | Borate, U. | Rampal, R. | +18

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[64]